To optimize the final formulation for a drug, it must meet many criteria beyond producing a safe and effective product. For example, it must be stable and amenable to various manufacturing steps, such ...

Codification replaces time-limited guidance authority after the first three cycles, establishing enduring parameters for 2029+ negotiations of up to 20 selected drugs spanning Part B and Part D.

Desire to Improve Therapeutic Proteins at Molecular Level Drives Bioformulation Advances While pharmaceutical formulations have always been part science, part art, the complexity of todays drugs has ...

A problem for biopharmaceutical companies comes as degraded proteins lead to ineffective and possibly dangerous medicines for their clients. Drug companies work on formulation development to protect ...

Here, MD simulations of neutral and anionic forms of CEL with different polymers, in aqueous solution, representing an in vivo environment, were performed, and compared with in vitro and in vivo ...

Stability is one of the main quality characteristics in formulation studies of prospective therapeutic biomolecules. Researchers depend on high-throughput screening techniques to reduce the funds, ...

Long-term stability of monoclonal antibodies to be used as biologics is a key aspect in their development. Therefore, its possible early prediction from accelerated stability studies is of major ...

Medications such as Ozempic and Mounjaro are composed of molecules called acylated peptides that are designed to circulate in the body and regulate insulin production. This enables adults with type 2 ...

Permanent rulemaking would replace IPAY 2026–2028 guidance, enabling predictable annual negotiations of up to 20 drugs and defined manufacturer agreement and renegotiation requirements. Formularies ...

Monoclonal antibodies have become one of the most established and clinically successful therapeutic modalities, supported by decades of advances in discovery, engineering, and manufacturing. Many ...

Researchers at ETH Zurich have identified a compound that targets a previously overlooked protein aggregation mechanism in ...